应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
MRK 默沙东
已收盘 12-30 16:00:00 EST
98.37
-1.33
-1.33%
盘后
98.24
-0.13
-0.13%
19:59 EST
最高
99.57
最低
98.27
成交量
684.87万
今开
99.57
昨收
99.70
日振幅
1.30%
总市值
2,488亿
流通市值
2,485亿
总股本
25.30亿
成交额
6.75亿
换手率
0.27%
流通股本
25.26亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
估值洼地之下，2025年这些生物科技股股价有望突破
老虎资讯综合 · 12-30 11:23
估值洼地之下，2025年这些生物科技股股价有望突破
默沙东涨0.13% 股价突破100美元大关
市场透视 · 12-27
默沙东涨0.13% 股价突破100美元大关
道指潜力股：2025年值得关注的6大可能赢家
老虎资讯综合 · 12-27
道指潜力股：2025年值得关注的6大可能赢家
【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。
金融界 · 12-27
【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。
多年心血付诸东流后，默沙东押宝下一个竞争焦点
CPHI制药在线 · 12-26
多年心血付诸东流后，默沙东押宝下一个竞争焦点
K药“药王”宝座将到期？Nature子刊预测司美格鲁肽合计销售额明年或超越它
每日经济新闻 · 12-24
K药“药王”宝座将到期？Nature子刊预测司美格鲁肽合计销售额明年或超越它
默克公司将停产治疗细菌感染的药物
路透中文 · 12-24
默克公司将停产治疗细菌感染的药物
默沙东上涨1.22%，报99.25美元/股
金融界 · 12-24
默沙东上涨1.22%，报99.25美元/股
默克集团在日本追加投资7000万欧元建设新研发中心
金吾财讯 · 12-23
默克集团在日本追加投资7000万欧元建设新研发中心
超20亿美元！默沙东要“卷”GLP-1
药智网 · 12-23
超20亿美元！默沙东要“卷”GLP-1
新“药王”诞生！K药挣扎，艾伯维、赛诺菲自免霸主争夺战开启
华尔街见闻 · 12-21
新“药王”诞生！K药挣扎，艾伯维、赛诺菲自免霸主争夺战开启
BUZZ--美国股票走势-Spire、铜矿商、Abercrombie & Fitch
Reuters · 12-21
BUZZ--美国股票走势-Spire、铜矿商、Abercrombie & Fitch
BUZZ--美国股票走势-Mission Produce、Sirius XM、嘉年华公司
Reuters · 12-20
BUZZ--美国股票走势-Mission Produce、Sirius XM、嘉年华公司
背景资料-减肥药开发商排队开发价值 1500 亿美元的市场
Reuters · 12-20
背景资料-减肥药开发商排队开发价值 1500 亿美元的市场
BUZZ-BMO 将默克公司评级下调至 "市场表现"，并下调预期收益率
路透中文 · 12-20
BUZZ-BMO 将默克公司评级下调至 "市场表现"，并下调预期收益率
默沙东(MRK.US)口服HIV疗法达两项关键3期试验主要终点
智通财经 · 12-20
默沙东(MRK.US)口服HIV疗法达两项关键3期试验主要终点
默沙东完成关于在研PD-1/VEGF双特异性抗体LM-299的全球独家许可协议
界面 · 12-20
默沙东完成关于在研PD-1/VEGF双特异性抗体LM-299的全球独家许可协议
加拿大蒙特利尔银行：下调Merck & Co评级
智通财经 · 12-20
加拿大蒙特利尔银行：下调Merck & Co评级
医疗大健康产业链月报：默沙东入局押注PD-1/VEGF双抗，板块内回购再贷款案例不断
华泰证券财富管理 · 12-20
医疗大健康产业链月报：默沙东入局押注PD-1/VEGF双抗，板块内回购再贷款案例不断
默沙东拟收购荷兰类器官公司HUB
金吾资讯 · 12-20
默沙东拟收购荷兰类器官公司HUB
加载更多
公司概况
公司名称：
默沙东
所属市场：
NYSE
上市日期：
--
主营业务：
默克制药公司于1970年在新泽西州注册成立。该公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。该公司的营运主要以产品为基础进行管理，包括两个经营分部：制药及动物保健国际。
发行价格：
--
{"stockData":{"symbol":"MRK","market":"US","secType":"STK","nameCN":"默沙东","latestPrice":98.37,"timestamp":1735592400000,"preClose":99.7,"halted":0,"volume":6848713,"hourTrading":{"tag":"盘后","latestPrice":98.2401,"preClose":98.37,"latestTime":"19:59 EST","volume":278134,"amount":27359395.2144,"timestamp":1735606770769},"delay":0,"floatShares":2525926440,"shares":2529635645,"eps":4.779697,"marketStatus":"已收盘","change":-1.33,"latestTime":"12-30 16:00:00 EST","open":99.57,"high":99.57,"low":98.27,"amount":675125554.006148,"amplitude":0.013039,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.779697,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1735635600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":-745790400000,"exchange":"NYSE","adjPreClose":99.7,"dividendRate":0.030904,"preHourTrading":{"tag":"盘前","latestPrice":99.45,"preClose":99.7,"latestTime":"09:29 EST","volume":3838,"amount":382697.30422,"timestamp":1735568997103},"postHourTrading":{"tag":"盘后","latestPrice":98.2401,"preClose":98.37,"latestTime":"19:59 EST","volume":278134,"amount":27359395.2144,"timestamp":1735606770769},"volumeRatio":0.653531,"optionData":{"bulkOrders":[{"symbol":"MRK","call":false,"expireDate":1737090000000,"strike":"115.0","timestamp":1735591240105,"price":16.6,"volume":2527,"amount":4194820,"type":"+"},{"symbol":"MRK","call":false,"expireDate":1737090000000,"strike":"110.0","timestamp":1735590118238,"price":11.35,"volume":1750,"amount":1986250,"type":"-"}]},"impliedVol":0.2783,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/MRK","defaultTab":"news","newsList":[{"id":"1131960883","title":"估值洼地之下，2025年这些生物科技股股价有望突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1131960883","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131960883?lang=zh_cn&edition=full","pubTime":"2024-12-30 11:23","pubTimestamp":1735529035,"startTime":"0","endTime":"0","summary":"经过数年不佳表现后，2025年生物科技股的趋势可能开始好转，但仍需谨慎挑选一些最具创新力的公司进行投资。“专利悬崖今年开始显现，但将在2025和2026年加剧，”他说。“总之，2025年下半年可能将Insmed转型为一家拥有多种商业化产品并在两个大型适应症中启动关键研究的公司。”摩根士丹利预计，2025年底Rocket的RP-A501基因疗法在二期试验中将取得关键数据，为其股价带来催化剂。","market":"us","thumbnail":"https://community-static.tradeup.com/news/2b99d2790d61544d0e8cfc36cd09b3ab","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/2b99d2790d61544d0e8cfc36cd09b3ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8400847a20bc64d46f119067e3c37e6c","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"估值洼地之下，2025年这些生物科技股股价有望突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","MRK","RHHBY","JAZZ","RCKT","ABBV","XBI","JNJ","LEGN"],"gpt_icon":1},{"id":"2494860493","title":"默沙东涨0.13% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2494860493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494860493?lang=zh_cn&edition=full","pubTime":"2024-12-27 22:36","pubTimestamp":1735310207,"startTime":"0","endTime":"0","summary":"北京时间2024年12月27日22时36分，默沙东股票出现异动，股价快速拉升0.13%。截至发稿，该股报100.00美元/股，成交量14.3461万股，换手率0.01%，振幅0.69%。最近的财报数据显示，该股实现营业收入167.15亿美元，净利润31.57亿美元，每股收益1.25美元，毛利122.74亿美元，市盈率20.91倍。默沙东股票所在的制药行业中，整体跌幅为0.24%。此外，默沙东还销售与动物健康相关的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412272236479851d43e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412272236479851d43e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1291159041.SGD","LU1571399168.USD","LU2324357040.USD","LU2106854487.HKD","MRK","BK4585","LU1066051498.USD","LU0985320562.USD","LU1057294990.SGD","LU1116320737.USD","SG9999014542.SGD","SG9999001440.SGD","LU1585245621.USD","LU2461242641.AUD","BK4559","LU1989772923.USD","SG9999001176.SGD","LU0211331839.USD","IE00BSNM7G36.USD","LU0289739699.SGD","LU0208291251.USD","LU1430594728.SGD","BK4550","SG9999002232.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU1037948541.HKD","LU0203345920.USD","LU0965508806.USD","SG9999015358.SGD","LU0006306889.USD","IE000M9KFDE8.USD","LU0122379950.USD","SG9999014567.USD","SG9999013999.USD","LU1941712264.USD","LU2361044949.HKD","LU0265550359.USD","LU1093756168.USD","IE00B4R5TH58.HKD","LU1917777945.USD","LU1934455194.USD","LU0266013472.USD","BK4007","LU2468319806.SGD","LU1066051225.USD","LU0861579265.USD","LU1116320901.HKD","BK4534","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"1179778710","title":"道指潜力股：2025年值得关注的6大可能赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=1179778710","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179778710?lang=zh_cn&edition=full","pubTime":"2024-12-27 11:01","pubTimestamp":1735268470,"startTime":"0","endTime":"0","summary":"分析师预计强生和安进的股价可能分别上涨超过21.5%，联合健康集团的股价可能上涨约28.9%。2024年，强生下跌了7%，安进下跌超过8%，联合健康集团下跌超过3%。默沙东、强生和安进预计也将在明年跻身道指股息收益率最高的前10名。英伟达是今年人工智能领域的明星股，也是华尔街看好2025年的另一只热门股票，其预期涨幅接近28%。该股在2024年飙升超过180%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/8d6d5143c1ab739fc940815d88c334a5","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/8d6d5143c1ab739fc940815d88c334a5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f101c6d3607fc94d58551567bf8c346e","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","JNJ","NVDA","MRK","UNH","CVX"],"gpt_icon":1},{"id":"2494289796","title":"【药企积极布局新赛道 聚焦三大研发方向】近期，国内药企在GLP-1领域进展消息不断。仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。创新药方面，12月18日，翰森制药宣布，公司授予默沙东口服GLP-1受体激动剂HS-10535全球独家许可权。此外，华东医药、甘李药业、恒瑞医药、通化东宝等多家上市公司亦于12月披露GLP-1领域研发进展。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。","url":"https://stock-news.laohu8.com/highlight/detail?id=2494289796","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494289796?lang=zh_cn&edition=full","pubTime":"2024-12-27 04:44","pubTimestamp":1735245849,"startTime":"0","endTime":"0","summary":"仿制药方面，12月24日，翰宇药业宣布，公司利拉鲁肽注射液正式登陆美国市场。业内人士表示，在火热的GLP-1赛道，海外巨头业绩持续超预期，国内研发进展加速，长效化、多靶点和口服药物研发是目前GLP-1赛道主要研发方向。从GLP-1产业链看，产业链中游和上游有望直接受益于全球多肽药物需求增长，下游的制剂厂商将分享最大的产业链价值。创新药方面，GLP-1市场仍处在蓝海阶段，疗效和上市进度是关键。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/27044446869434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","MRK","LU1585245621.USD","GLP","SG9999015341.SGD","IE00BLSP4452.SGD","159992","IE00BJT1NW94.SGD","LU1328615791.USD","LU0238689110.USD","LU2461242641.AUD","000963","LU0861579265.USD","LU1064130708.USD","BK4516","BK0187","LU1917777945.USD","LU1066051811.HKD","LU1066051498.USD","SG9999015358.SGD","IE00B1BXHZ80.USD","LU1974910355.USD","300199","IE00BFTCPJ56.SGD","LU0965509101.SGD","SG9999014559.SGD","LU0211331839.USD","LU1064131003.USD","600867","03692","SG9999001176.SGD","SG9999014567.USD","BK1589","LU0405327494.USD","IE00BN8TJ469.HKD","BK0239","LU0122379950.USD","LU1699723380.USD","06978","LU1934455863.HKD","600276","LU1934455277.USD","LU1934455194.USD","LU1037948897.HKD","IE00BBT3K403.USD","LU1116320901.HKD","LU1989772840.SGD","SG9999002232.USD","603087","BK4533"],"gpt_icon":0},{"id":"2494854984","title":"多年心血付诸东流后，默沙东押宝下一个竞争焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2494854984","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494854984?lang=zh_cn&edition=full","pubTime":"2024-12-26 19:21","pubTimestamp":1735212101,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。而默沙东要押注的下一个竞争焦点，也为创新药企带来启发。目前，距离K药专利到期只剩下三年左右的时间，默沙东在为寻找下一个重磅炸弹焦虑，不过并未取得理想成绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2361044865.SGD","LU2361045086.USD","LU1093756325.SGD","LU0203347892.USD","LU1941712348.USD","LU0289739699.SGD","SG9999002232.USD","LU2023250843.SGD","LU1974910355.USD","LU2468319806.SGD","MRK","SG9999001440.SGD","LU1037948541.HKD","LU0203345920.USD","LU1934455863.HKD","LU2324357040.USD","SG9999013999.USD","BK4559","IE00B2B36J28.USD","SG9999001176.SGD","LU1941712264.USD","BK4533","BK4588","LU1989772840.SGD","LU1291159041.SGD","LU0106261372.USD","LU0861579265.USD","LU2361044949.HKD","SGXZ57979304.SGD","LU1934455277.USD","LU1934455194.USD","LU1061106388.HKD","LU2023250504.SGD","IE00BJT1NW94.SGD","LU1116320901.HKD","LU0070302665.USD","LU1983299246.USD","LU0122379950.USD","BK4550","BK4585","LU1057294990.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","LU1989771016.USD","LU1037948897.HKD","LU1989772923.USD","IE0009355771.USD","LU0266013472.USD","IE00B1BXHZ80.USD","BK4534"],"gpt_icon":0},{"id":"2493035802","title":"K药“药王”宝座将到期？Nature子刊预测司美格鲁肽合计销售额明年或超越它","url":"https://stock-news.laohu8.com/highlight/detail?id=2493035802","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493035802?lang=zh_cn&edition=full","pubTime":"2024-12-24 23:34","pubTimestamp":1735054492,"startTime":"0","endTime":"0","summary":"据报道，《Nature》旗下杂志近日刊发了一份2025年药物销售预测。该报告预测，从单药角度看，默沙东旗下帕博利珠单抗（Keytruda，以下简称K药）销售额将于2025年达到309.9亿美元，有望卫冕“药王”宝座。诺和诺德的“降糖版”司美格鲁肽和礼来的降糖版替尔泊肽（均属于GLP-1制剂）紧随其后。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412243277833932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412243277833932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BLSP4452.SGD","BK4534","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU2089984988.USD","SGXZ57979304.SGD","LU1093756168.USD","SG9999002224.SGD","SG9999014542.SGD","LU1571399168.USD","BK4007","LU1934455194.USD","LU0289739699.SGD","IE000M9KFDE8.USD","LU1066051811.HKD","LU0058720904.USD","BK4559","BK4550","LU2112291526.USD","IE00BBT3K403.USD","IE0002141913.USD","LU1941712264.USD","BK4585","LU2324357040.USD","BK4516","LU1974910355.USD","LU0070302665.USD","LU1430594728.SGD","MRK","LU1291159041.SGD","LU1066051225.USD","LU2361044949.HKD","IE00BJT1NW94.SGD","LU1989772923.USD","LU0203345920.USD","LU2468319806.SGD","LU1941712348.USD","LU2023250504.SGD","LU2361045086.USD","SG9999001440.SGD","LU1093756325.SGD","SG9999013999.USD","LU1983299246.USD","LU0203347892.USD","LU0211331839.USD","LU0320765489.SGD","LU0208291251.USD","LU1116320737.USD","LU0965509283.SGD"],"gpt_icon":0},{"id":"2493174877","title":"默克公司将停产治疗细菌感染的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2493174877","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493174877?lang=zh_cn&edition=full","pubTime":"2024-12-24 07:34","pubTimestamp":1734996879,"startTime":"0","endTime":"0","summary":"默克公司将停产治疗细菌感染的药物路透12月23日 - 美国食品和药物管理局网站周一显示，默克公司MRK.N将停产其治疗一种可导致致命腹泻的细菌感染的药物。该抗体药物Zinplava于2016年首次获得监管机构批准，用于预防艰难梭菌感染复发。CDI一般由长期使用抗生素引起，可能导致致命的腹泻和结肠发炎。监管机构的网站显示，Zinplava将于1月31日停产，但没有说明停产原因。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nL4T3NO18G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361044865.SGD","LU2361045086.USD","LU1093756325.SGD","LU0965509010.AUD","LU0265550359.USD","LU0289739699.SGD","IE00BBT3K403.USD","MRK","LU2468319806.SGD","LU0238689110.USD","SG9999001440.SGD","LU1037948541.HKD","LU2112291526.USD","LU0203345920.USD","LU0985320562.USD","LU1934455863.HKD","SG9999013999.USD","SG9999001176.SGD","IE0002141913.USD","LU2089984988.USD","LU0106261372.USD","LU0965509101.SGD","LU0861579265.USD","LU0965509283.SGD","LU2361044949.HKD","LU0234572021.USD","SGXZ57979304.SGD","LU1934455277.USD","LU1934455194.USD","LU2023250504.SGD","SG9999014542.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","SG9999014559.SGD","LU1066053197.SGD","BK4007","LU1983299246.USD","IE00BFTCPJ56.SGD","BK4585","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0965508806.USD","LU1066051811.HKD","IE00BSNM7G36.USD","SG9999001176.USD","LU1037948897.HKD","LU0211331839.USD","IE0009355771.USD","LU0266013472.USD","BK4534"],"gpt_icon":0},{"id":"2493179088","title":"默沙东上涨1.22%，报99.25美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2493179088","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493179088?lang=zh_cn&edition=full","pubTime":"2024-12-24 04:04","pubTimestamp":1734984283,"startTime":"0","endTime":"0","summary":"12月24日，默沙东(MRK)盘中上涨1.22%，截至04:04，报99.25美元/股，成交4.14亿美元。财务数据显示，截至2024年09月30日，默沙东收入总额485.44亿美元，同比增长6.73%；归母净利润133.74亿美元，同比增长740.6%。大事提醒：12月20日，默沙东获蒙特利尔资本市场下调评级至Market Perform，目标价下调至105美元。2025年2月4日，默沙东将于(美东)盘前披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/24040446729747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999001176.SGD","LU1934455863.HKD","IE00B4R5TH58.HKD","IE0002141913.USD","LU1093756168.USD","LU0058720904.USD","IE00BSNM7G36.USD","BK4585","LU1941712348.USD","LU0965509283.SGD","LU1066051811.HKD","LU1061106388.HKD","LU0320765489.SGD","SG9999015358.SGD","IE00BN8TJ469.HKD","SG9999001440.SGD","IE00BJJMRZ35.SGD","SG9999015341.SGD","IE000M9KFDE8.USD","LU1116320737.USD","SG9999013999.USD","IE00B1BXHZ80.USD","LU0238689110.USD","LU1699723380.USD","LU1066051225.USD","SG9999001176.USD","SG9999014542.SGD","LU0208291251.USD","SG9999014559.SGD","BK4534","LU2023250504.SGD","LU2106854487.HKD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU1430594728.SGD","SG9999014567.USD","LU0965509010.AUD","LU1934455277.USD","SG9999014575.USD","LU1291159041.SGD","BK4559","LU1934455194.USD","IE00BLSP4239.USD","LU0234572021.USD","LU0861579265.USD","IE0009355771.USD","LU0289739699.SGD","MRK","LU1066051498.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2493914733","title":"默克集团在日本追加投资7000万欧元建设新研发中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2493914733","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493914733?lang=zh_cn&edition=full","pubTime":"2024-12-23 16:37","pubTimestamp":1734943079,"startTime":"0","endTime":"0","summary":"金吾财讯 | 德国默克集团宣布，将在日本静冈的工厂投资超过7000万欧元建设一个新的先进材料研发中心。这笔最新的投资使得默克集团自2021年起在静冈工厂的投资总额超过了1.2亿欧元。预计这个新的研发中心将在2026年正式开始运作。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NzFhNTI4MGUwYzI0YmU3ZWQ0MDcxNDc2MTkyOTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzFhNTI4MGUwYzI0YmU3ZWQ0MDcxNDc2MTkyOTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"283584","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXE","LU1934455863.HKD","LU0211331839.USD","IE0009355771.USD","SGXZ57979304.SGD","LU2461242641.AUD","LU0070302665.USD","SG9999001176.USD","IE00BFTCPJ56.SGD","LU1066051225.USD","MRK","LU0203345920.USD","LU0238689110.USD","LU1023059063.AUD","LU1571399168.USD","SG9999002232.USD","BK4534","LU2361044865.SGD","LU2468319806.SGD","LU2106854487.HKD","LU1037948897.HKD","LU1699723380.USD","IE00BSNM7G36.USD","LU1941712348.USD","SG9999013999.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","EURmain","IE00BLSP4239.USD","LU0265550946.USD","LU1989772923.USD","LU1585245621.USD","LU2089984988.USD","LU1093756325.SGD","LU1974910355.USD","SG9999014542.SGD","BK4007","IE00BLSP4452.SGD","BK4516","EUO","SG9999002224.SGD","LU0965508806.USD","LU1061106388.HKD","LU1430594728.SGD","SG9999014559.SGD","IE000M9KFDE8.USD","MEURmain","LU0320765489.SGD","IE00B4R5TH58.HKD","LU1116320901.HKD"],"gpt_icon":0},{"id":"2493789732","title":"超20亿美元！默沙东要“卷”GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2493789732","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493789732?lang=zh_cn&edition=full","pubTime":"2024-12-23 14:44","pubTimestamp":1734936243,"startTime":"0","endTime":"0","summary":"诺和诺德的司美格鲁肽销售额连年攀升，2023年更是达到了212.01亿美元，成为全球首个GLP-1药物中的“百亿美元俱乐部”成员，大有取代默沙东K药的趋势，成为新一代的“药王”；礼来的替尔泊肽同样表现强劲，市场竞争力不容小觑。诚益生物获1.85亿美元首付款，还有资格高达18.25亿美元相关款项及特许权使用费，阿斯利康再次将目光聚焦在小分子口服GLP-1领域。再到近日默沙东引进翰森制药的口服小分子GLP-1药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223145030a203f6ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223145030a203f6ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2461242641.AUD","BK4590","GLP","LU0965509010.AUD","LU0965509283.SGD","BK4534","LU1430594728.SGD","LU1917777945.USD","LU1941712264.USD","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","LU0238689110.USD","LU1066051498.USD","BK4559","MRK","LU0070302665.USD","LU0234572021.USD","LU0265550946.USD","BK4533","LU0211331839.USD","BK4585","LU1699723380.USD","SG9999002224.SGD","BK4588","SG9999001440.SGD","BK4144","LU2089984988.USD","SG9999014559.SGD","LU1116320737.USD","IE00B4R5TH58.HKD","LU1116320901.HKD","LU1066051811.HKD","LU1934455194.USD","LU2112291526.USD","LU0965508806.USD","IE00BBT3K403.USD","LU0861579265.USD","LU0985320562.USD","LU0006306889.USD","IE00BSNM7G36.USD","LU1291159041.SGD","LU2106854487.HKD","LU1941712348.USD","LU1989771016.USD","SG9999002232.USD","IE00B1BXHZ80.USD","BK4516","LU0203345920.USD"],"gpt_icon":0},{"id":"2493328281","title":"新“药王”诞生！K药挣扎，艾伯维、赛诺菲自免霸主争夺战开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2493328281","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493328281?lang=zh_cn&edition=full","pubTime":"2024-12-21 14:50","pubTimestamp":1734763811,"startTime":"0","endTime":"0","summary":"K药“药王”保卫战，礼来和诺和诺德的GLP-1市场份额之战以及艾伯维与赛诺菲的自免“霸主”之争。三场战事背后，释放出MNC怎样的焦虑与野心？","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/d115eb0e-d03c-44c1-86f1-8942111d4036.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d115eb0e-d03c-44c1-86f1-8942111d4036.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3737515","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3737515","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4516","LU1983299246.USD","LU1037948541.HKD","LU0234572021.USD","LU1989771016.USD","LU1093756168.USD","MRK","LU0070302665.USD","LU2361045086.USD","LU1093756325.SGD","SG9999001440.SGD","BK4559","LU1037948897.HKD","LU0238689110.USD","LU0006306889.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","IE00BFTCPJ56.SGD","BK4007","LU1974910355.USD","LU1989772923.USD","LU2023250843.SGD","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0265550359.USD","BK4550","LU1934455194.USD","LU0965508806.USD","LU0985320562.USD","BK4533","LU0203345920.USD","LU1571399168.USD","LU0122379950.USD","IE0002141913.USD","IE00BLSP4239.USD","BK4588","SG9999014559.SGD","SG9999015341.SGD","LU1941712348.USD","IE00BLSP4452.SGD","SG9999013999.USD","BK4534","LU2324357040.USD","SGXZ57979304.SGD","LU1057294990.SGD","LU1066051498.USD","LU1699723380.USD","LU1066051811.HKD","LU0965509283.SGD","SG9999001176.SGD"],"gpt_icon":0},{"id":"2493270934","title":"BUZZ--美国股票走势-Spire、铜矿商、Abercrombie & Fitch","url":"https://stock-news.laohu8.com/highlight/detail?id=2493270934","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493270934?lang=zh_cn&edition=full","pubTime":"2024-12-21 02:41","pubTimestamp":1734720117,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串：[STXBZ］ * The Day Ahead 新闻通讯： * 新闻早报通讯： 12月20日 - 华尔街主要股指周五在震荡交投中跳涨，原因是一份冷于预期的通胀报告缓解了美联储预测2025年仅两次降息引发的一些市场担忧。美国东部时间13:30，道琼斯工业平均指数 上涨1.47%，报42963.15点；标普500指数 上涨1.36%，报5947.02点；纳斯达克综合指数 上涨1.34%，报19632.11点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVO","VKTX","GALT","SQQQ","PSQ","SOL","SNPS","ALT","IONS","KMX","QLD","SIRI","MNQmain","QID","USJW.SI","USAW.SI","GPCR",".IXIC",".SPX","DXD","SCCO","WGO","DOG","CCL","DDM","AADI","ISSC","AMGN","X",".DJI","HUMA","FCX","NVIW.SI","LU1037948897.HKD","SR","NQmain","NEM","FDX","APLM","MRK","DJX","LU0719512351.SGD","TQQQ","LU1934455194.USD","TSYW.SI","SDOW"],"gpt_icon":1},{"id":"2492440770","title":"BUZZ--美国股票走势-Mission Produce、Sirius XM、嘉年华公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2492440770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492440770?lang=zh_cn&edition=full","pubTime":"2024-12-20 23:39","pubTimestamp":1734709181,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串：[STXBZ］ * The Day Ahead 新闻通讯： * The Morning News Call时事通讯： 12月20日 - 标普500指数和纳斯达克指数周五下跌，原因是市场担心明年的高利率问题，尽管一份冷于预期的通胀报告抑制了损失。美国东部时间10:30，道琼斯工业平均指数 上涨0.61%，报42601.62点。标普500指数 上涨0.49%，报5895.94点；纳斯达克综合指数 上涨0.44%，报19457.30点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNCE","DJX","DXD",".IXIC","MNQmain","KMX","XM","DNMR","VKTX","DOG","SNPS","USAW.SI","X","TSYW.SI","AMGN","NVIW.SI","AVO","ALT","NVO","MRK","SOL","SQQQ","WGO","KUKE","IIPR","AADI","GPCR","TQQQ","SDOW","SIRI","GALT","QID","PSQ","FDS","QLD",".SPX","IONS","FDX","NQmain","USJW.SI",".DJI","APLM","LLY","HUMA","CLW","DDM","CCL"],"gpt_icon":1},{"id":"2492544239","title":"背景资料-减肥药开发商排队开发价值 1500 亿美元的市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2492544239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492544239?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:59","pubTimestamp":1734706761,"startTime":"0","endTime":"0","summary":"与Wegovy试验68周后体重减轻约15%相比， 。11 月，该公司称，在一项早期试验中，该药物帮助 9 名接受最高 100 毫克剂量治疗的患者在 28 天后平均减轻了 8.2% 的体重。该公司在 8 月份表示，它将在今年下半年开始与其他制药公司洽谈开发和商业化 petrelintide 的潜在合作事宜。Zealand 公司目前正在进行一项中期研究，在没有 2 型糖尿病的超重或肥胖患者中测试 petrelintide。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU2461242641.AUD","LU0708995401.HKD","LU0097036916.USD","LU1868837300.USD","LU2491050071.SGD","MRK","LU2242652126.USD","LU0354030511.USD","LU0203201768.USD","LU1093756325.SGD","LU2211815571.USD","LU2361045086.USD","LU1037948897.HKD","ALT","IE000M9KFDE8.USD","LU2089984988.USD","OPK","IE00BJT1NW94.SGD","GPCR","LU2602419157.SGD","SG9999015945.SGD","IE00B2B36J28.USD","LU1989772923.USD","LU1917777945.USD","PFE","LU1868836757.USD","SG9999002224.SGD","LU0471298777.SGD","SG9999018865.SGD","LU2361044865.SGD","LU0466842654.USD","LU2237443382.USD","LU0122379950.USD","LU0861579265.USD","IE0002141913.USD","LU0965509010.AUD","IE00BK4W5M84.HKD","LU1941712348.USD","AMGN","LU0079474960.USD","BK4534","LLY","SGXZ57979304.SGD","SGXZ99366536.SGD","SG9999018857.SGD","LU0203202063.USD","NVO","IE00B1BXHZ80.USD","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2492449639","title":"BUZZ-BMO 将默克公司评级下调至 \"市场表现\"，并下调预期收益率","url":"https://stock-news.laohu8.com/highlight/detail?id=2492449639","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492449639?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:14","pubTimestamp":1734704052,"startTime":"0","endTime":"0","summary":"BUZZ-BMO 将默克公司评级下调至 \"市场表现\"，并下调预期收益率12月20日 - ** 制药商默克MRK.N股价在盘前交易中下跌1%至98.54美元 ** 经纪公司BMO Capital Markets将默克公司的评级从 \"跑赢大盘 \"下调至 \"市场表现\"；将目标价从136美元下调至105美元。** 认为 \"默克不再是制药领域的'稳定漩涡'\"。** 截至上一交易日收盘，默克股价累计下跌 8.7(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4T3NL0VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"gpt_icon":0},{"id":"2492653443","title":"默沙东(MRK.US)口服HIV疗法达两项关键3期试验主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2492653443","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492653443?lang=zh_cn&edition=full","pubTime":"2024-12-20 21:20","pubTimestamp":1734700830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，默沙东今日宣布两项关键性3期试验MK-8591A-051与MK-8591A-052达成主要终点。默沙东计划在未来的科学会议上公布这些试验的详细结果，并将相关数据提交监管机构。Doravirine是由默沙东开发的一种每日一次的口服创新非核苷逆转录酶抑制剂。它通过与HIV-1病毒的逆转录酶结合，防止HIV-1病毒将RNA转化为DNA，从而阻断HIV-1病毒复制。它已在美国获批用于治疗未接受过抗病毒疗法的成年HIV-1感染患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"默沙东(MRK.US)口服HIV疗法达两项关键3期试验主要终点","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1057294990.SGD","LU1066051225.USD","IE0009355771.USD","LU0965509101.SGD","LU0234572021.USD","LU1066051811.HKD","IE00B1BXHZ80.USD","LU2023250504.SGD","SG9999002232.USD","LU0122379950.USD","LU1023059063.AUD","LU1571399168.USD","LU1989771016.USD","LU1116320737.USD","LU0211331839.USD","LU0058720904.USD","LU2361045086.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","IE00BN8TJ469.HKD","IE00BJT1NW94.SGD","LU0265550946.USD","SG9999001176.SGD","BK4533","LU0985320562.USD","SG9999001440.SGD","LU1585245621.USD","BK4516","MRK","LU0203347892.USD","BK4007","LU0006306889.USD","LU1037948897.HKD","LU2106854487.HKD","LU0106261372.USD","IE00B4R5TH58.HKD","LU1934455277.USD","LU0965509010.AUD","LU2324357040.USD","LU0965509283.SGD","SG9999002224.SGD","LU1093756325.SGD","LU1983299246.USD","LU1934455194.USD","SG9999014567.USD","SG9999015358.SGD","LU2461242641.AUD","LU0289739699.SGD","LU1066053197.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2492126744","title":"默沙东完成关于在研PD-1/VEGF双特异性抗体LM-299的全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492126744","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492126744?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:16","pubTimestamp":1734697012,"startTime":"0","endTime":"0","summary":"默沙东12月20日宣布，完成与礼新医药关于新型在研PD-1/VEGF双特异性抗体LM-299的全球独家许可协议。默沙东将开发、生产和商业化LM-299。默沙东将产生首付款相关5.88亿美元（或约合每股0.18美元）的税前费用，并计入2024年第四季度通用及非通用会计准则财务数据。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还有资格获得最高27亿美元的里程碑付款，其中包括预计在2025年完成技术转让后支付的三亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220201652a1fdcba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220201652a1fdcba8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2023250843.SGD","LU1169590202.USD","LU1974910355.USD","LU2468319806.SGD","LU2361044865.SGD","IE00BN8TJ469.HKD","SG9999001440.SGD","LU0289739699.SGD","SG9999013999.USD","BK4559","LU1983299246.USD","IE00BSNM7G36.USD","IE000M9KFDE8.USD","LU0211331839.USD","LU1066051225.USD","LU0106261372.USD","LU1023059063.AUD","LU0861579265.USD","LU2324357040.USD","LU0238689110.USD","LU0070302665.USD","LU1934455863.HKD","SG9999014542.SGD","SG9999015341.SGD","LU1037948541.HKD","LU2361044949.HKD","LU1989772923.USD","BK4023","LU0965509101.SGD","LU1066053197.SGD","LU1066051811.HKD","IE00BJT1NW94.SGD","LU1585245621.USD","PD","LU2461242641.AUD","LU0122379950.USD","LU0208291251.USD","LU0320765489.SGD","IE00BLSP4239.USD","LU1917777945.USD","SG9999001176.SGD","SG9999014567.USD","IE00B1BXHZ80.USD","LU1061106388.HKD","LU2112291526.USD","MRK","LU2089984988.USD","SGXZ57979304.SGD","LU0266013472.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2492284448","title":"加拿大蒙特利尔银行：下调Merck & Co评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492284448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492284448?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:32","pubTimestamp":1734694360,"startTime":"0","endTime":"0","summary":"加拿大蒙特利尔银行：下调Merck & Co(MRK.US)评级，由优于大市调整至大市一致评级,目标价由136.00美元调整至105.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220210112ab872b5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220210112ab872b5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BMO"],"gpt_icon":0},{"id":"2492100499","title":"医疗大健康产业链月报：默沙东入局押注PD-1/VEGF双抗，板块内回购再贷款案例不断","url":"https://stock-news.laohu8.com/highlight/detail?id=2492100499","media":"华泰证券财富管理","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492100499?lang=zh_cn&edition=full","pubTime":"2024-12-20 16:18","pubTimestamp":1734682720,"startTime":"0","endTime":"0","summary":"波士顿科学宣布年内第四笔收购11月25日，波士顿科学宣布同意收购输液泵制造商Intera Oncology，具体金额未公开。二者均已获得FDA批准。公司11月30日公告，2024年第六次临时股东大会通过了延长定增事项股东大会决议有效期和延长董事会授权有效期两项议案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220164416a1fd3725&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220164416a1fd3725&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BK4533","IE0009355771.USD","LU0965509010.AUD","LU1169590202.USD","IE00BLSP4239.USD","LU0965508806.USD","PD","LU1023059063.AUD","LU0006306889.USD","LU1941712264.USD","BK4585","LU0203345920.USD","LU0070302665.USD","LU1989772840.SGD","SG9999014559.SGD","LU1061106388.HKD","LU0234572021.USD","LU1066051811.HKD","SG9999002224.SGD","LU2361045086.USD","LU1093756168.USD","LU1066051225.USD","LU2112291526.USD","LU2089984988.USD","BK4534","SG9999014542.SGD","LU2324357040.USD","LU1116320901.HKD","BK4588","LU0861579265.USD","LU1983299246.USD","IE00BN8TJ469.HKD","LU0106261372.USD","LU2461242641.AUD","BK4559","LU1989772923.USD","SGXZ57979304.SGD","BK4007","LU1066051498.USD","SG9999002232.USD","LU0965509101.SGD","SG9999014567.USD","LU0122379950.USD","LU1941712348.USD","SG9999013999.USD","SG9999015341.SGD","BK4550","IE00BJJMRZ35.SGD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2492647484","title":"默沙东拟收购荷兰类器官公司HUB","url":"https://stock-news.laohu8.com/highlight/detail?id=2492647484","media":"金吾资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492647484?lang=zh_cn&edition=full","pubTime":"2024-12-20 14:58","pubTimestamp":1734677927,"startTime":"0","endTime":"0","summary":"金吾财讯 | 默沙东(MRK)宣布，目前已签署计划收购HUB Organoids Holding B.V.（HUB）的最终协议。类器官是功能上类似于器官的细胞培养模型，有潜力加速药物开发，提升对不同人群疾病治疗的理解，并减少行业对动物实验的依赖。HUB是类器官领域的先驱，总部位于荷兰乌特勒支，拥有约70名员工。交易预计将于2024年12月底完成，交易条款尚未披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220145921a1fd043a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220145921a1fd043a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066051498.USD","LU1917777945.USD","LU2361044865.SGD","LU1093756325.SGD","LU0203347892.USD","LU0265550359.USD","LU1941712348.USD","IE00BBT3K403.USD","SG9999002232.USD","LU2023250843.SGD","LU1974910355.USD","LU2468319806.SGD","MRK","SG9999001440.SGD","LU1037948541.HKD","LU2112291526.USD","LU1934455863.HKD","BK4559","IE00B2B36J28.USD","IE0002141913.USD","BK4533","LU0006306889.USD","LU1941712264.USD","BK4588","LU1989772840.SGD","LU2089984988.USD","LU0965509101.SGD","LU2361044949.HKD","LU0234572021.USD","SG9999015358.SGD","SGXZ57979304.SGD","SG9999014542.SGD","LU1699723380.USD","SG9999014559.SGD","SG9999015341.SGD","LU1116320901.HKD","LU0070302665.USD","BK4550","BK4585","LU0965508806.USD","SG9999014575.USD","SG9999002224.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU1037948897.HKD","IE0009355771.USD","LU0266013472.USD","BK4534"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.merck.com","stockEarnings":[{"period":"1week","weight":0.0168},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.1231},{"period":"6month","weight":-0.1947},{"period":"1year","weight":-0.0834},{"period":"ytd","weight":-0.0855}],"compareEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":-0.0064},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.0933},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.2518}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"默克制药公司于1970年在新泽西州注册成立。该公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。该公司的营运主要以产品为基础进行管理，包括两个经营分部：制药及动物保健国际。","yearOnYearQuotes":[{"month":1,"riseRate":0.568182,"avgChangeRate":0.009892},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.000396},{"month":3,"riseRate":0.636364,"avgChangeRate":-0.002321},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018595},{"month":5,"riseRate":0.644444,"avgChangeRate":0.018719},{"month":6,"riseRate":0.511111,"avgChangeRate":0.01265},{"month":7,"riseRate":0.488889,"avgChangeRate":0.003443},{"month":8,"riseRate":0.488889,"avgChangeRate":0.001677},{"month":9,"riseRate":0.533333,"avgChangeRate":-0.006327},{"month":10,"riseRate":0.533333,"avgChangeRate":0.018591},{"month":11,"riseRate":0.711111,"avgChangeRate":0.028573},{"month":12,"riseRate":0.6,"avgChangeRate":0.014041}],"exchange":"NYSE","name":"默沙东","nameEN":"Merck"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"默沙东,MRK,默沙东股票,默沙东股票老虎,默沙东股票老虎国际,默沙东行情,默沙东股票行情,默沙东股价,默沙东股市,默沙东股票价格,默沙东股票交易,默沙东股票购买,默沙东股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}